Ulcerative colitis
Conditions
Brief summary
Percentage of clinical and endoscopic remission after remission induction phase.
Detailed description
Percentage of clinical response after remission induction phase., Percentage of clinical response at 52 wks., Percentage of clinical remission at 52 wks., Percentage of endoscopic remission or endoscopic improvement after the remission induction phase and at 52 wks., Percentage of laboratory remissions after the remission induction phase and at 52 weeks., Percentage of deep remissions after the remission induction phase and at 52 wks., Comparison of patients' quality of life after the remission induction phase and at 52 wks., Comparison of the number and type of adverse events and serious adverse events after the remission induction phase and at 52 wks.
Interventions
DRUGUSTEKINUMAB
DRUGINFLIXIMAB
Sponsors
Medical University Of Lodz
Eligibility
Sex/Gender
All
Age
18 Years to 64 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of clinical and endoscopic remission after remission induction phase. | — |
Secondary
| Measure | Time frame |
|---|---|
| Percentage of clinical response after remission induction phase., Percentage of clinical response at 52 wks., Percentage of clinical remission at 52 wks., Percentage of endoscopic remission or endoscopic improvement after the remission induction phase and at 52 wks., Percentage of laboratory remissions after the remission induction phase and at 52 weeks., Percentage of deep remissions after the remission induction phase and at 52 wks., Comparison of patients' quality of life after the remission induction phase and at 52 wks., Comparison of the number and type of adverse events and serious adverse events after the remission induction phase and at 52 wks. | — |
Countries
Poland
Outcome results
None listed